PODD Insulet Corporation
Margins already near target; tubeless franchise worth roughly market price, not a bargain.
The story
Insulet's Omnipod is the leading tubeless, patch-style insulin pump. Its moat comes from pharmacy-channel distribution, pay-as-you-go pricing and integration with CGMs and automated insulin delivery algorithms. The business is in late high growth: type 1 penetration is maturing, while expansion into type 2 diabetes and international markets gives it several more years of double-digit growth before competition from Tandem, Medtronic, Beta Bionics and patch-pump entrants pushes it toward mature med-tech economics.
The facts on margins changed: TTM operating margin is already 19.1% on $3.19B of revenue, so my previous 20% target was effectively reached. I raised it to 23% (a 15% relative move) to reflect pharmacy-channel scale and gross-margin leverage, still below peak-promotional levels because competition caps pricing. Growth moves up slightly to 16% to match TTM momentum, and sales-to-capital moves to 1.3 to match the observed 1.29. Beta, failure probability and the 8-year horizon stay unchanged.
Value drivers
| Revenue growth (Y1) | 16.0% |
| Terminal growth | 3.5% |
| Forecast horizon | 8y |
| Target operating margin | 23.0% |
| Years to target margin | 6 |
| Sales-to-capital | 1.30 |
| Beta | 1.10 |
| Failure probability | 3.0% |
| Cost of capital (WACC) | 9.4% |
| Terminal WACC | 9.0% |
Valuation bridge
| PV of explicit FCFF | 2.56B |
| PV of terminal value | 7.93B |
| Equity value | 9.95B |
| ÷ shares → per share | $143.44 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 3.70B | 16.0% | 19.7% | 531.27M | 392.52M | 138.75M | 126.87M |
| 2 | 4.23B | 14.2% | 20.4% | 626.90M | 404.50M | 222.39M | 185.93M |
| 3 | 4.75B | 12.4% | 21.0% | 727.42M | 403.96M | 323.46M | 247.27M |
| 4 | 5.26B | 10.6% | 21.7% | 829.85M | 388.91M | 440.94M | 308.20M |
| 5 | 5.72B | 8.9% | 22.3% | 930.58M | 358.11M | 572.47M | 365.88M |
| 6 | 6.13B | 7.1% | 23.0% | 1.03B | 311.23M | 714.31M | 417.43M |
| 7 | 6.45B | 5.3% | 23.0% | 1.08B | 249.09M | 830.66M | 443.85M |
| 8 | 6.68B | 3.5% | 23.0% | 1.12B | 173.65M | 943.88M | 461.15M |
Key risks
- Competing type 2 diabetes products (GLP-1 drugs reducing insulin need, rival patch pumps) slow penetration
- Reimbursement or pharmacy pricing pressure compresses per-pod economics
- Product recalls or manufacturing and quality issues at pod-production scale
Catalysts
- Type 2 diabetes coverage wins and faster adoption of basal-only users
- International Omnipod 5 launches and new CGM integrations widening the addressable market